Amgen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amgen Inc (AMGN)
The Amgen share price today is 362.17, view NASDAQ AMGN stock exchange data. Track the latest Amgen share price with real-time updates on AMGN stock performance including market cap, day range, 52-week range and dividend yield. Access AMGN charts, earnings dates and analyst estimates to support your investment decisions.
362.18
-1.44(-0.40%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
361.16
364.90
52 wk Range
269.77
391.29
AMGN is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
361.16364.90
52 wk Range
269.77391.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.77%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.77%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AMGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
355.66
Downside
-1.80%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Amgen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Amgen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Amgen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
14 Buy
17 Hold
3 Sell
Ratings:
34 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 355.66
(-1.80% Downside)
Amgen Inc SWOT Analysis
Biotech Powerhouse | Amgen's robust financial health and strategic positioning in key therapeutic areas underscore its potential for sustained growth in the competitive biotechnology landscape |
Obesity Market Gambit | Delve into Amgen's ambitious pursuit of the obesity treatment market with MariTide, a novel bispecific GLP-1 agonist/GIP antagonist in Phase 3 trials |
Pipeline Prowess | Explore Amgen's diverse R&D pipeline, featuring promising candidates in oncology and immunology, poised to drive future revenue growth and market expansion |
Analyst Optimism | Discover why analysts maintain a bullish outlook on Amgen, with price targets ranging from $310 to $346, reflecting confidence in the company's strategic direction |
Amgen Inc Earnings Call Summary for Q1/2026
- Amgen Q1 2026 EPS of $5.15 beat forecast of $4.80 by 7.29%; revenue reached $8.62B vs. expected $8.59B, though stock fell 2.43% after-hours.
- Company raised 2026 revenue guidance to $37.1B-$38.5B and non-GAAP EPS to $21.70-$23.10, emphasizing emerging growth drivers over legacy brands.
- Six key growth products drove 70% of sales with 24% YoY growth; Repatha and Evenity showed particularly strong performance in the quarter.
- Non-GAAP operating margin held at 45% with $1.5B free cash flow; dividend increased 6% to $2.52 per share from Q1 2025.
- Management cited Q1 as 'springboard year' foundation while navigating patent expirations through innovation investments in high unmet medical need areas.
Last Updated: 09-05-2026, 08:38 pm
Read Full TranscriptEarnings
Latest Release
30-04-2026
EPS / Forecast
5.15 / 4.80
Revenue / Forecast
8.62B / 8.59B
Compare AMGN to Peers and Sector
Metrics to compare | AMGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.2x | 18.9x | −0.4x | |
PEG Ratio | 0.80 | 0.15 | 0.00 | |
Price/Book | 21.3x | 2.0x | 2.6x | |
Price / LTM Sales | 5.3x | 2.2x | 3.0x | |
Upside (Analyst Target) | −2.4% | 26.5% | 51.9% | |
Fair Value Upside | Unlock | 14.1% | 9.1% | Unlock |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Amgen (AMGN) Share Price Today?
The Amgen share price today is 362.18.
What is the current Amgen (AMGN) share price and day range?
As of 10-07-2026, the Amgen share price is 362.18, with a previous close of 363.62. The share price has ranged from 361.16 to 364.90 today, while the 52-week range spans from 269.77 to 391.29.
What Is the Amgen Market Cap?
As of today, Amgen market cap is 195.38B.
Does Amgen Pay Dividends? What's The Current Dividend Yield?
The Amgen dividend yield is 2.77%.
What Is the Amgen (AMGN) Share Price Target?
The average 12-month share price target for Amgen is 355.66, with a high estimate of 427 and a low estimate of 215. 14 analysts recommend buying, while 3 suggest selling, with an overall rating of Buy and -1.80% Downside potential.
What Is Amgen's Earnings Per Share (TTM)?
The Amgen EPS (TTM) is 14.37.
When Is the Next Amgen Earnings Date?
Amgen will release its next earnings report on 04-08-2026.
From a Technical Analysis Perspective, Is AMGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Amgen Trade On?
Amgen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Amgen?
The stock symbol for Amgen is "AMGN."
How Many Times Has Amgen Stock Split?
Amgen has split 5 times.
How Many Employees Does Amgen Have?
Amgen has 31500 employees.
What Is the AMGN Premarket Price?
AMGN's last pre-market stock price is 364.00. The pre-market share volume is 4,310.00, and the stock has changed by 0.38, or 0.10%.
What Is the AMGN After Hours Price?
AMGN's last after hours stock price is 364.99, the stock has changed by 1.37, or 0.38%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.